| Molecule Proprietary Name |
Molecule Generic Name |
Molecule Type |
Indication |
Biological Target |
Role |
| Imfinzi |
Durvalumab |
mAb |
Oncology |
PD-L1 |
Bioanalytical Lead, Submission Lead, PK, ADA, and Nab Assay Lead, Outsourcing Lead |
| Enhertu |
trastuzumab-deruxtecan |
ADC |
Oncology |
HER2 |
Immunogenicity Lead, Submission Team, PK (LBA), ADA, and Nab Assay Lead, Outsourcing Lead, Co-Collaboration Lead |
| Imjudo |
Tremelimumab |
mAb |
Oncology |
CTLA4 |
Bioanalytical Lead, Submission Lead, PK, ADA, and Nab Assay Lead, Outsourcing Lead |
| Saphnelo |
Anifrolumab |
mAb |
SLE (Lupus) |
IFNar |
Bioanalytical Lead, Submission Lead, PK, ADA, and Nab Assay Lead, Outsourcing Lead |
| Beyfortus |
Nirsevimab |
mAb |
Infectious Disease |
RSV (F-protein) |
Bioanalytical Lead, Submission Lead, PK, ADA, and Nab Assay Lead, Outsourcing Lead |
| AiRuiKa |
Camrelizumab |
mAb |
Oncology |
PD-1 |
ISI Preparation |
| Evusheld |
AZD7442 (tixagevimab and cilgavimab) |
2 mAbs |
COVID-19 |
COVID-19 |
Immunogenicity Strategy, Outsourcing Lead, ADA and Nab Assay Lead |
| Bydureon Bcise |
exenatide |
peptide |
T2DM |
GLP-1 |
Bioanalytical Lead, Submission Lead, ADA Assay Lead, Outsourcing Lead |
| Trulicity |
dulaglutide |
peptide |
T2DM |
GLP-1 |
Key Client Contact, PK Assay Lead |
| Kynamro |
Mipomersen, ISIS301012 |
ASO |
Hyper- cholesterolemia |
apoB-100 |
Key Client Contact, PK Assay Lead, ADA Assay Lead |
| Xigris |
drotrecogin alfa |
Enzyme |
Sepsis |
Activated Protein C |
Key Client Contact, PK Assay Lead, ADA Assay Lead, Nab Assay Lead |
| Mounjaro |
GIP-GLP |
peptide |
T2DM, Obesity |
GLP-1, GIP |
Key Client Contact, Discovery Bioanalysis PK Assay lead |
| Covishield, Vaxzevria |
ChAdOx1 |
vaccine |
COVID-19 |
COVID-19 |
Preclinical Strategy, molecular lead, DART study lead |
| Kisunla |
donanemab |
mAb |
Alheimer's |
Amyloid-beta |
Key Client Contact, PD Assay Lead |
| Cyramza |
ramucirumab |
mAb |
Oncology |
VEGFR2 |
Key Client Contact, PD Assay Lead |